Susceptible bacteria can survive antibiotic treatment in the mammalian gastrointestinal tract without evolving resistance

Cell Host Microbe. 2024 Mar 13;32(3):396-410.e6. doi: 10.1016/j.chom.2024.01.012. Epub 2024 Feb 14.

Abstract

Antibiotic resistance and evasion are incompletely understood and complicated by the fact that murine interval dosing models do not fully recapitulate antibiotic pharmacokinetics in humans. To better understand how gastrointestinal bacteria respond to antibiotics, we colonized germ-free mice with a pan-susceptible genetically barcoded Escherichia coli clinical isolate and administered the antibiotic cefepime via programmable subcutaneous pumps, allowing closer emulation of human parenteral antibiotic dynamics. E. coli was only recovered from intestinal tissue, where cefepime concentrations were still inhibitory. Strikingly, "some" E. coli isolates were not cefepime resistant but acquired mutations in genes involved in polysaccharide capsular synthesis increasing their invasion and survival within human intestinal cells. Deleting wbaP involved in capsular polysaccharide synthesis mimicked this phenotype, allowing increased invasion of colonocytes where cefepime concentrations were reduced. Additionally, "some" mutant strains exhibited a persister phenotype upon further cefepime exposure. This work uncovers a mechanism allowing "select" gastrointestinal bacteria to evade antibiotic treatment.

Keywords: Escherichia coli; antibiotic persistence; antibiotic resistance; antibiotic tolerance; bacterial survival; bacterial virulance; mammalian GI tract.

MeSH terms

  • Animals
  • Anti-Bacterial Agents* / pharmacology
  • Anti-Bacterial Agents* / therapeutic use
  • Bacteria
  • Cefepime
  • Escherichia coli*
  • Gastrointestinal Tract / microbiology
  • Humans
  • Mammals
  • Mice
  • Microbial Sensitivity Tests
  • Polysaccharides

Substances

  • Cefepime
  • Anti-Bacterial Agents
  • Polysaccharides